National Drug Authority ( NDA) was established by an Act of Parliament, the National Drug Policy and Authority (NDP & A) Act, Cap 206 of the laws of Uganda. The Authority is mandated to ensure the availability at all times of essential, efficacious, and cost effective drugs to the entire population of Uganda, as a…
The National Drug Authority informs the general public that Simon Esemu is not an employee of the Authority He was apprehended soliciting money for licensing drug outlet operators with forged identity card impersonating one of the Authority staff by name of Peter Emalu The Authority advises the public to always apply legal steps of acquiring…
Valsartan is a drug used in the treatment of high blood pressure, usually in combination with other anti-hypertensive drugs. It has been discovered that some brands of this drug were manufactured using an ingredient potentially contaminated with an impurity called N-nitrosodimethylamine (NDMA), which is classified as a probable human carcinogen (a substance that could cause…
National Drug Authority wishes to inform you that retention of Human and Veterinary products on the drug register for financial year 2018 / 2019 will run from 1st July, 2018 to 1st September 2018. All products that will not have been retained by then will not appear on the monthly drug registers. Retention invoices will…
In accordance with the National Drug Policy and Authority Act (Cap 206), and Regulations on importation and exportation of drugs (S.I 34, 2014), National Drug Authority hereby informs you that importation of drugs is to be conducted by entities with a valid license to operate a pharmacy and a valid import license. In regard to…
National Drug Authority wishes to notify all applicants for the following products for registrations (download Link) that the applications will be dismissed with effect from 30-June-2018 for failure to respond to additional information requested for. This is in line with section 35(4) of The National Drug Policy and Authority Act Cap 206.
